News

Pharmaceutical Technology2h
Obesity therapies and the multi-indication momentum: how industry is responding
The rise of GLP-1 agonist therapies has transformed obesity treatment, delivering unprecedented results and revealing their ...
Trump won't force Medicaid to cover GLP-1s for obesity. A few states are doing it anyway.
South Carolina Medicaid approved GLP-1s to treat obesity, placing it among the few state programs covering the drugs. But ...
Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...
Here's Why Obesity Drugs Are Changing the Food We Buy
Hundreds of thousands of people around the world are now on weight loss drugs like Wegovy, known as GLP-1s. The food industry is taking notice too, with big companies leaning into more nutritional ...
Eli Lilly: Obesity Drug Development To Go Beyond That Of Zepbound
Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...
Novo Nordisk is betting on a CEO shake-up to regain its weight loss drug edge over Eli Lilly
Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...
This biotech’s stock rockets on oral obesity-drug partnership with Wegovy parent
Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...
Wall Street Expects This Obesity Drug Stock to Skyrocket 35% Over the Next 12 Months
However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to ...
Novo CEO’s Shock Exit: Who Will Take Over Obesity Drug Giant?
Novo Nordisk A/S’s surprise decision to replace Chief Executive Officer Lars Fruergaard Jorgensen has triggered a race to ...